Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immucell Corp. (ICCC)
NASDAQ:ICCC
Holding ICCC?
Track your performance easily
Earnings Data
Report Date
Feb 25, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2024
|% Change Since: 24.93%
|Next Earnings Date:Feb 25, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted improved sales and EBITDA, indicating strong demand for the First Defense product line, and an improved cash position. However, challenges remain with gross margins, production contamination, regulatory delays, and increased cost of goods sold.Company Guidance
During the ImmuCell Corporation Q3 2024 earnings call, significant guidance was provided around the company's recent challenges and future outlook. President and CEO Michael Brigham highlighted an 11% increase in product sales for the quarter compared to the same period in 2023, with sales growth of 51% and 46% for the nine- and twelve-month periods, respectively. Despite this, the gross margin remained below their target of 35% to 40%, improving slightly from 23% to 26% over the comparable three-month periods. Brigham noted a positive shift in EBITDA, moving from negative $95,000 in Q3 2023 to positive $119,000 in Q3 2024. The company addressed contamination issues that plagued production until April 2024, which were partly responsible for yield losses and gross margin deterioration. Remediation steps have been successful, with no contamination events since. ImmuCell has also bolstered its cash position from $979,000 at the end of 2023 to approximately $3.8 million by September 2024, partly through an at-the-market offering, while product development expenses have been reduced as they await FDA approval for Re-Tain. The company is optimistic about future sales and operational improvements, while also exploring strategic partnerships to support new product launches.Increase in Product Sales
Product sales increased by 11%, 51%, and 46% during the 3-, 9-, and 12-month periods ended September 30, 2024, respectively, compared to the same periods in 2023.
Improvement in EBITDA
EBITDA improved from negative $95,000 during the 3-month period ended September 30, 2023, to positive $119,000 during the same period in 2024.
Strong Customer Demand
The company is experiencing strong customer demand for the First Defense product line.
Cash Position Improvement
The company’s cash position improved from $979,000 as of December 31, 2023, to approximately $3.8 million as of September 30, 2024.
---
ICCC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ICCC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $3.53 | $3.60 | +1.98% |
| Aug 13, 2024 | $3.76 | $3.60 | -4.26% |
| May 14, 2024 | $5.48 | $4.88 | -10.95% |
| Feb 27, 2024 | $5.14 | $5.22 | +1.56% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Immucell Corp. (ICCC) report earnings?
Immucell Corp. (ICCC) is schdueled to report earning on Feb 25, 2025, TBA Not Confirmed.
What is Immucell Corp. (ICCC) earnings time?
Immucell Corp. (ICCC) earnings time is at Feb 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ICCC EPS forecast?
Currently, no data Available
---